- Home
- NIKI vs BRTX Comparison
NIKI vs BRTX Comparison
Compare NIKI & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIKI | BRTX |
|---|---|---|
| Founded | N/A | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.4M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NIKI | BRTX |
|---|---|---|
| Price | $7.85 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.0K | ★ 310.1K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $0.16 |
| 52 Week High | $10.39 | $1.89 |
Technical Indicators
Market Signals| Indicator | NIKI | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.76 |
| Support Level | N/A | $0.19 |
| Resistance Level | N/A | $0.24 |
| Average True Range (ATR) | 0.00 | 0.01 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 65.71 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.